Pfizer-BioNTech COVID-19 vaccine effective from day 11 post 1st dose, says study
Sydney: A team of researchers suggests that one dose of the Pfizer-BioNTech vaccine could be sufficient in providing a robust immune response 11 days after inoculation against severe acute respiratory syndrome (SARS-CoV-2).
According to the researchers, including Heidi E. Drummer from Monash University in Australia, the second 'booster' dose of the vaccine may not increase vaccine efficacy against SARS-CoV-2.
The findings, published as a preprint on the medRxiv* server, could help shape policy as vaccine rollout has been slow in countries such as the US and Canada. This could also increase with vaccine distribution efforts in developing countries where supplies have been scarce.
For the study, the team re-examined Pfizer-BioNTech phase III trial data from day 1 to 111 in the placebo and experimental groups.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.